An mRNA-Based Respiratory Syncytial Virus Vaccine Elicits Strong Neutralizing Antibody Responses and Protects Rodents Without Vaccine-Associated Enhanced Respiratory Disease
Based on the preclinical immunogenicity and efficacy data, LVRNA007 could be a potential promising vaccine for prophylaxis of RSV infection.
Authors
- Yucai Peng (ORCID: https://orcid.org/0009-0001-4865-0956)
- Shaoyi Chen (ORCID: https://orcid.org/0000-0003-2253-5041)
- Jiaru Cai
- Jun Liu (ORCID: https://orcid.org/0000-0002-5815-2483)
- Shuang Li (ORCID: https://orcid.org/0000-0001-8857-724X)
- Qi Liu (ORCID: https://orcid.org/0009-0001-2370-3353)
- Liping Luo (ORCID: https://orcid.org/0000-0002-6510-8421)
- Haiyan Long (ORCID: https://orcid.org/0000-0002-1901-4969)
- Jianglong Li
- Zhendong Zhang (ORCID: https://orcid.org/0009-0001-2991-9593)
Publication Details
- Journal
- Vaccines
- Published
- 2025-01-09
- DOI
- https://doi.org/10.3390/vaccines13010052
- Citations
- 6
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 8.13